Compare AbCellera Biologics Inc (ABCL) vs Arm Holdings plc (ARM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Arm Holdings plc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Arm Holdings plc trades at $298.72 (market cap $320.88B). The key difference: Arm Holdings plc is far larger — about 136.5× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ABCL | ARM | |
|---|---|---|
Market Cap | $2.35B | $320.88B |
Sector | Health | Technology |
52-Week High | $8.12 | $439.46 |
52-Week Low | $2.78 | $104.55 |
Enterprise Value | $1.99B | $317.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ARM Holdings trades at $322.24, up 2.21% today but showing bearish technical momentum with key support at $317. The stock maintains strong fundamentals with 97.54% gross margins and consistent earnings beats, though valuation ratios remain elevated (P/E 379.11). Recent news highlights AI-driven growth in licensing and data center expansion, despite a 35% pullback from June 2026 peaks.
Outlook is mixed: robust AI demand and analyst optimism (74% buy ratings) support upside potential, but high valuation and technical weakness pose near-term risks. The consensus price target of $321.65 aligns with current levels, suggesting cautious optimism amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →
